ALK-Abello A/S
CSE:ALK B

Watchlist Manager
ALK-Abello A/S Logo
ALK-Abello A/S
CSE:ALK B
Watchlist
Price: 223 DKK 2.2%
Market Cap: 45.2B DKK
Section:
 

Relative Value

The Relative Value of one ALK B stock under the Base Case scenario is 232.15 DKK. Compared to the current market price of 223 DKK, ALK-Abello A/S is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALK B Relative Value
Base Case
232.15 DKK
Undervaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8.1
P/S
P/S
Price to Sales
8.1
vs History
15
vs Industry
23
Median 3Y
6
Median 5Y
6.7
Industry
2.6
Forward
7.6
More Details
44.9
P/E
P/E
Price to Earnings
44.9
vs History
76
vs Industry
11
Median 3Y
47
Median 5Y
57.1
Industry
21.6
Forward
41.7
More Details
31.9
P/OCF
P/OCF
Price to OCF
31.9
vs History
79
vs Industry
16
Median 3Y
34.9
Median 5Y
46.5
Industry
16.5
More Details
348.3
P/FCFE
P/FCFE
Price to FCFE
348.3
vs History
25
vs Industry
3
Median 3Y
128
Median 5Y
104.1
Industry
22.5
More Details
8
P/B
P/B
Price to Book Value
8
vs History
28
vs Industry
12
Median 3Y
6.3
Median 5Y
7.1
Industry
2.3
More Details
8.1
EV/S
EV/S
Enterprise Value to Sales
8.1
vs History
19
vs Industry
22
Median 3Y
6
Median 5Y
6.7
Industry
2.9
Forward
7.6
More Details
12.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
12.3
vs History
28
vs Industry
24
Median 3Y
9.5
Median 5Y
10.7
Industry
5.5
More Details
27.6
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
27.6
vs History
57
vs Industry
16
Median 3Y
26.8
Median 5Y
29.4
Industry
13
Forward
24.3
More Details
33.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
33.4
vs History
71
vs Industry
16
Median 3Y
34
Median 5Y
40.4
Industry
16.6
Forward
29.1
More Details
31.7
EV/OCF
EV/OCF
Enterprise Value to OCF
31.7
vs History
79
vs Industry
17
Median 3Y
34.8
Median 5Y
47
Industry
15.8
More Details
225.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
225.4
vs History
28
vs Industry
6
Median 3Y
174.1
Median 5Y
185.1
Industry
19.1
More Details
6.4
EV/IC
EV/IC
Enterprise Value to IC
6.4
vs History
7
vs Industry
18
Median 3Y
4.5
Median 5Y
5.1
Industry
1.9
More Details

Multiples Across Competitors

ALK B Competitors Multiples
ALK-Abello A/S Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
ALK-Abello A/S
CSE:ALK B
49.4B DKK 8.1 44.9 27.6 33.4
US
Eli Lilly and Co
NYSE:LLY
985.4B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
506.1B USD 5.5 20.1 16.5 21.4
CH
Roche Holding AG
SIX:ROG
251.4B CHF 4.1 26.7 11.4 13.3
UK
AstraZeneca PLC
LSE:AZN
209.2B GBP 4.8 29.8 107.9 157.9
CH
Novartis AG
SIX:NOVN
206.7B CHF 4.6 18 11.5 14.8
US
Merck & Co Inc
NYSE:MRK
246.7B USD 3.8 13 9.2 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
142.4B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
DK
ALK-Abello A/S
CSE:ALK B
Average P/E: 26
44.9
24%
1.9
US
Eli Lilly and Co
NYSE:LLY
53.5
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.7
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.8
38%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBITDA: 401.3
27.6
22%
1.3
US
Eli Lilly and Co
NYSE:LLY
35.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.5
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.4
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
107.9
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
ALK-Abello A/S
CSE:ALK B
Average EV/EBIT: 1 713.1
33.4
25%
1.3
US
Eli Lilly and Co
NYSE:LLY
38.5
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.3
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
157.9
23%
6.9
CH
Novartis AG
SIX:NOVN
14.8
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
8%
1.3

See Also

Summary
ALK B intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALK B stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALK B stock valuation using valuation multiples.
Wall Street Estimates
ALK B price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALK B stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 303,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.